ClinicalTrials.gg
CompletedNCT04434196Updated Jul 25, 2024

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase 1 interventional study of CC-99282 and Obinutuzumab in Lymphoma, Non-Hodgkin, sponsored by Celgene. Completed at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-25.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb — 2 open to participants now, 5 under way, none of them phase 3. Lymphoma, Non-Hodgkin · Bristol-Myers Squibb.

Enrollment
37th of 46
16 · median 58
Started
2020
with 3 others
Phase 1
18 of 50
none open now
Registered
41st of 50
by date

Among the 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb, this one is the 37th largest by enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2020, is one of 18 in phase 1, and was the 41st registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

2 of the 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Read the detailed description

All eligible subjects must be relapsed or refractory to at least 2 prior lines of therapy, one of which must have included an inhibitor of B-cell receptor signaling (approved Bruton's tyrosine kinase inhibitor [BTKi] or Phosphoinositide 3-kinase inhibitor [PI3Ki]) or venetoclax. The dose escalation (Part A) will evaluate the safety, tolerability, and PK of escalating doses of CC-99282 given in combination with intravenous obinutuzumab to determine the MTD and RP2D of CC-99282 when given in combination with obinutuzumab. The dose expansion (Part B) may occur at the MTD established in the dose escalation phase, or at an alternative tolerable dosing schedule, based on review of safety, PK and PD data from Part A.

03

Conditions studied

  • Lymphoma, Non-Hodgkin

Keywords

  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Safety
  • Efficacy
  • CC-99282
  • Obinutuzumab
  • Relapsed
  • Refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is ≥18 years of age
  2. (ECOG) performance status of 0-2.
  3. Must have a documented diagnosis of CLL/SLL requiring treatment (IwCLL Guidelines for the Diagnosis and Treatment of CLL). In addition presence of clinically determined by at least one of the factors listed:

    • nodal lesion that measures ≥ 1.5 cm in longest dimension (LD) and ≥ 1.0 cm in longest perpendicular dimension (LPD), or
    • spleen that measures ≥ 14 cm in longest vertical dimension (LVD) with a minimum of 2 cm enlargement, or
    • liver that measures ≥ 20 cm in LVD with a minimum of 2 cm enlargement, or
    • peripheral blood B lymphocyte count > 5000/uL
  4. All eligible subjects must be after or be refractory to >2 one of which must have included an approved BTK inhibitor.
  5. Must meet the following laboratory parameters:

    1. (ANC) ≥ 1,500 cells/mm\^3 or ≥ 1000 cells/mm\^3 if secondary to bone marrow involvement by disease, without growth factor support for 7 days (14 days if pegfilgastrim).
    2. count ≥ 75,000 cells/mm\^3 (100 x 10\^9/L) or ≥ 50,000 cells/mm\^3 (50 x 10\^9/L) if secondary to bone marrow involvement by disease, without transfusion for 7 days.
    3. Serum (AST/SGOT) or alanine transaminase (ALT/SGPT) \< 3.0 x (ULN).
    4. Serum \< 1.5 x ULN unless due to Gilbert's syndrome.
    5. Calculated of ≥ 60 ml/min.

Exclusion criteria

Exclusion Criteria:

  1. Presence of any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  2. Prior stem cell transplant (SCT)/bone marrow transplant within 12 months of signing the ICF. Subjects who received allogeneic SCT ≥ 12 months before signing the ICF may be eligible provided there is no ongoing and no ongoing immune suppression therapy.
  3. Subject has received prior CAR-T or other T-cell targeting treatment (approved or ) ≤ 4 weeks prior to starting CC-99282.
  4. Subject has received prior therapy with CRBN-modulating drug (eg, lenalidomide, avadomide/CC-122, pomalidomide) ≤ 4 weeks prior to starting CC-99282.
  5. History of second with of ≤ 2 years or requirement of therapy that would confound study results.
  6. Peripheral neuropathy ≥ Grade 2.
  7. History of to lenalidomide, pomalidomide, thalidomide.
  8. Impaired cardiac function or cardiac disease.
  9. Persistent diarrhea or malabsorption ≥ Grade 2, despite medical management.
  10. Active disease transformation (ie, Richter's Syndrome)
  11. Uncontrolled/active hemolytic anemia or thrombocytopenia
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    CC-99282 + obinutuzumab

    Escalating doses of CC-99282 administered orally once daily on intermittent schedules with obinutuzumab IV infusion 1000 mg up to 2 years in Part A. CC-99282 administered orally once daily at MTD or alternative tolerating dosing schedule with obinutuzumab IV infusion 1000 mg up to 2 years in Part B.

    Drug: CC-99282 · Drug: Obinutuzumab

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT)

    Number of subjects with a DLT

    Time frame: Up to Cycle 2 Day 14 (each cycle is 28 days)

  2. Maximum tolerated dose (MTD)

    The highest dose of CC-99282 in combination with obinutuzumab associated with acceptable safety and tolerability

    Time frame: Up to Cycle 2 Day 14 (each cycle is 28 days

  3. Adverse Events (AEs)

    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.

    Time frame: From first subjects first visit until 28 days after last subject discontinued study treatment

Secondary outcomes

  1. Pharmacokinetics - Cmax

    Maximum observed plasma concentration

    Time frame: Up to Cycle 2 Day 14 (each cycle is 28 days)

  2. Pharmacokinetics - AUC

    Area under the plasma concentration-time curve

    Time frame: Up to Cycle 2 Day 14 (each cycle is 28 days)

  3. Pharmacokinetics - Tmax

    Time to Cmax

    Time frame: Up to Cycle 2 Day 14 (each cycle is 28 days)

  4. Pharmacokinetics - T-HALF

    Terminal-phase elimination half-life

    Time frame: Up to Cycle 2 Day 14 (each cycle is 28 days)

  5. Pharmacokinetics - CLT/F

    Apparent total clearance of the drug from plasma after oral administration

    Time frame: Up to Cycle 2 Day 14 (each cycle is 28 days)

  6. Pharmacokinetics - Vz/F

    Apparent volume of distribution during terminal phase after non-intravenous administration

    Time frame: Up to Cycle 2 Day 14 (each cycle is 28 days)

  7. Objective response rate (ORR)

    Sum of complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR), partial response (PR), partial response with lymphocytosis (PRL) determined by iwCLL criteria

    Time frame: Up to approximately 3 years

  8. Duration of response (DoR)

    Time from first documentation of response (≥ PR) to the first documentation of PD or death

    Time frame: Up to approximately 3 years

  9. Progression free survival

    Time from first dose of CC-99282 to the first occurrence of disease progression or death from any cause

    Time frame: Up to approximately 3 years

  10. Overall survival

    Time from first dose of CC-99282 to death from any cause

    Time frame: Up to approximately 3 years

  11. Complete response with incomplete marrow recovery (CRi)

    As assessed by International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria

    Time frame: Up to approximately 3 years

  12. Nodular partial response (nPR)

    As assessed by iwCL and International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria

    Time frame: Up to approximately 3 years

  13. Partial response (PR)

    As assessed by iwC and International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria

    Time frame: Up to approximately 3 years

  14. Partial response with lymphocytosis (PRL)

    As assessed by iwCLL and International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria

    Time frame: Up to approximately 3 years

07

Study locations

15 sites
  • Local Institution - 106
    Boston, Massachusetts 02215, United States
  • Local Institution - 104
    Columbus, Ohio 43210, United States
  • Local Institution - 101
    Portland, Oregon 97201-3098, United States
  • Local Institution - 107
    Dallas, Texas 75390, United States
  • Local Institution - 403
    Innsbruck, 6020, Austria
  • Local Institution - 401
    Salzburg, 5020, Austria
  • Local Institution - 402
    Wien, 1090, Austria
  • Local Institution - 201
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 202
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution - 304
    Pamplona, Navarra 31008, Spain
  • Local Institution - 302
    Barcelona, 08035, Spain
  • Local Institution - 306
    Madrid, 28027, Spain
  • Local Institution - 301
    Madrid, 28041, Spain
  • Local Institution - 303
    Salamanca, 37007, Spain
  • Local Institution - 305
    Valencia, 46010, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in May 2024, 41 months.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's 41 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2020
First posted
Jun 16, 2020
StartActual
Dec 21, 2020
Primary completionActual
May 21, 2024
CompletionActual
May 21, 2024
Last update
Jul 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04434196
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jun 16, 2020
Start date
Dec 21, 2020
Primary completion
May 21, 2024
Completion
May 21, 2024
Last update
Jul 25, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golcadomide

Start the discussion